公司控股股东帅放文先生持有公司股份 853,574,906 股，占本公司总股本的 41.38%，计划在本公告发布之日起 15 个交易日后的 3 个月内（即 2026 年 4 月 23 日至 2026 年 7 月 22 日）以集中竞价或大宗交易方式合计减持公司股份不超 过 42,000,000 股，即不超过本公司总股本的 2.04%。以上股东在任意连续九十个 自然日内通过证券交易所集中竞价交易减持股份的总数不超过公司股份总数的 1%；在任意连续九十个自然日内，通过大宗交易方式减持股份的总数不超过公 司股份总数的 2%。 湖南尔康制药股份有限公司（以下简称"公司"）于近日收到控股股东帅放 文先生出具的《股份变动计划告知函》，现将有关事项公告如下： 一、计划减持股东的基本情况 证券代码：300267 证券简称：尔康制药 公告编号：2026-004 湖南尔康制药股份有限公司 关于控股股东减持公司股份的预披露公告 控股股东帅放文先生保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 公司控股股东帅放文先生持 ...

Group 1 - The A-share market saw a collective decline in lithium mining stocks, with companies such as Huayou Cobalt and Zhongmin Resources dropping over 6% [1] - Other companies like Tibet Summit and Western Mining also experienced significant declines, falling over 5%, while companies including Cangge Mining, Erkang Pharmaceutical, Ganfeng Lithium, Salt Lake Industry, and Tianqi Lithium dropped over 4% [1] - The main contract for lithium carbonate experienced a substantial drop, reaching a maximum decline of 12.99% during the trading session, with a price of 150,860 yuan per ton [1]

证券代码：300267 证券简称：尔康制药 公告编号：2026-003 湖南尔康制药股份有限公司 关于审计机构变更项目质量复核人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司（以下简称"公司"）于 2025 年 11 月 27 日召 开了第六届董事会第二次会议，并于 2025 年 12 月 16 日召开 2025 年第二次临时 股东会，审议通过了《关于续聘 2025 年度审计机构的议案》，同意公司续聘天 健会计师事务所（特殊普通合伙）（以下简称"天健事务所"）为公司 2025 年 度财务报告及内部控制审计机构。 近日，公司收到天健事务所出具的《关于变更项目质量复核人的函》，现将 具体情况公告如下： 一、本次变更项目质量复核人的基本情况 天健事务所作为公司 2025 年度财务报告及 2025 年度内部控制的审计机构， 原委派陈素素女士作为公司审计项目的质量复核人，为公司提供审计服务。鉴于 陈素素女士工作调整，天健事务所指派尹志彬先生接替陈素素女士作为公司 2025 年度审计项目的质量复核人，继续完成相关工作。 二、本次变更后项目 ...

Group 1 - The lithium mining sector experienced a significant surge in early trading, with companies like Erkang Pharmaceutical and Keli Yuan hitting the daily limit up, and Yanhai Co. rising by 9.2%, bringing its market value to over 200 billion yuan [1][2] - Sigma Lithium, a leading global lithium producer, saw its stock price increase by nearly 30%, while other companies like Yabo and Chilean Mining Chemical also reported gains of approximately 5% and 4% respectively [2][3] Group 2 - Zimbabwe, the world's fourth-largest lithium producer, announced a suspension of all raw and lithium concentrate exports to enhance mineral regulation and accountability, allowing only companies with valid mining rights and approved processing plants to export [3] - UBS projected a supply shortage in the global lithium carbonate market by 2026, raising its price forecast to $26,000 per ton (approximately 180,000 yuan per ton), indicating the potential for a third price cycle in the lithium market [3]

Industry Overview - The lithium mining sector is experiencing a significant surge, driven by expectations of a contraction in global lithium supply and a recent stabilization in lithium prices, leading to heightened performance recovery expectations in the industry [2][3] - Zimbabwe, the largest lithium exporter in Africa, has announced a suspension of lithium concentrate and raw ore exports, which is expected to tighten short-term supply and potentially drive lithium prices significantly higher [3] Company Highlights - Erkang Pharmaceutical's subsidiary, Erkang Mining, established in Nigeria, is engaged in lithium exploration and mining, positioning the company to benefit from rising lithium prices [6] - Jinyuan Co. is advancing its lithium salt project and has acquired a 15% stake in Ali Lithium Source to enhance its lithium resource reserves, which will benefit from the industry's improving conditions [6] - Salt Lake Co. has successfully implemented a technology upgrade that has improved lithium recovery rates to 95%, positioning it as a leading domestic player in lithium extraction [6] - Tianqi Lithium's Greenbush lithium spodumene mine in Australia is the largest and highest-grade lithium project currently in production, with an annual capacity of 1.62 million tons, set to benefit from the industry's growth [6] Market Dynamics - The lithium mining and processing sectors are expected to see increased demand for equipment due to expansions in lithium mining projects and new lithium salt production capacities, benefiting companies involved in the manufacturing of lithium mining and processing equipment [5] - The recovery in lithium prices is anticipated to enhance profitability for lithium salt processing companies, especially those with strong cost control and scalable production capabilities [4]

Group 1 - The core viewpoint of the article is that Erkang Pharmaceutical's subsidiary, Erkang Mining, is engaged in lithium mining exploration, extraction, and processing in Nigeria, and has shown steady business development since its production began in the fourth quarter of 2024 [1] - The company reported continuous improvement in production output since the commencement of operations [1]

Group 1 - The stock dynamics of Erkang Pharmaceutical (300267) are primarily focused on trading data and changes in capital flow [1] - As of February 12, 2026, the balance of margin financing and securities lending was 329 million yuan, a decrease of 2.55% from the previous day, indicating short-term outflow pressure [1] - The stock price has shown a downward trend over the past week, with a decline of 13.52% from February 6 to February 13, closing at 3.71 yuan, down from a high of 3.85 yuan on February 6 [1] Group 2 - The trading activity has been volatile, with a turnover rate of 3.67% on February 10, which dropped to 2.27% on February 12 [1] - On February 13, there was a net inflow of main funds amounting to 8.948 million yuan, although large orders showed a net outflow, reflecting market divergence [1]

Group 1 - The core viewpoint of the news is that Erkang Pharmaceutical experienced a significant drop in stock price, with an 8.83% decline on January 30, resulting in a trading volume of 546 million yuan [1] - As of January 30, the financing balance of Erkang Pharmaceutical reached 365 million yuan, accounting for 4.63% of its market capitalization, indicating a high level of financing activity [1] - The company reported a net financing outflow of 14.02 million yuan on January 30, with a total financing buy amount of 37.85 million yuan and a repayment of 51.87 million yuan [1] Group 2 - As of September 30, the number of shareholders of Erkang Pharmaceutical increased by 14.88% to 49,100, while the average circulating shares per person decreased by 12.95% to 28,966 shares [2] - For the period from January to September 2025, Erkang Pharmaceutical achieved a revenue of 1.006 billion yuan, representing a year-on-year growth of 17.81%, and a net profit attributable to shareholders of 39.58 million yuan, up 255.40% year-on-year [2] - The company has distributed a total of 540 million yuan in dividends since its A-share listing, with 61.88 million yuan distributed in the last three years [3]

Group 1 - The A-share market saw a collective decline in lithium mining stocks, with notable drops including Nepean Mining falling nearly 12% and several other companies hitting the daily limit down [1] - The main contract for lithium carbonate experienced a limit down, with a decrease of 11%, currently priced at 148,200 yuan per ton [1] Group 2 - Specific stock performances included Nepean Mining down 11.46% with a market cap of 8.152 billion yuan, and other companies like Meiyuan Co. and Tibet Zhufeng both down 10% [2] - Other significant declines included Western Mining down 9.99% with a market cap of 84.8 billion yuan, and Tianqi Lithium down 8.74% with a market cap of 88.5 billion yuan [2]

Group 1 - The company expects a net profit attributable to shareholders of between -325 million to -385 million yuan for the fiscal year 2025, primarily impacted by asset impairment losses [1] - The company's main business has shown steady growth compared to the same period in 2024, benefiting from the operation of the lithium ore beneficiation plant project in Nigeria, with expected revenue from lithium concentrate business exceeding 200 million yuan [1] - The cash flow from operating activities has significantly increased compared to the same period in 2024, indicating a healthy operational status [1] Group 2 - The company is accelerating its industrial layout in Africa, investing a total of 18 million dollars in comprehensive formulation and injection production projects in Tanzania and Nigeria [2] - The ongoing deepening of China-Africa cooperation provides significant opportunities for Chinese companies to expand overseas, aligning with the company's strategy to enhance its presence in the African renewable energy and healthcare sectors [2] - The company is expected to solidify its long-term development foundation as mining project capacities continue to be released and pharmaceutical manufacturing bases are established, with future performance likely to return to a growth trajectory [2]